Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Repligen Corporation Common Stock (RGEN) Price & Performance

Duolingo IncTrade
Repligen Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Repligen Corporation Common Stock — how do they compare? Duolingo Inc trades at $138.12 (market cap $6.55B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 138 Days and Repligen Corporation Common Stock for 0 Days on average.

DUOLRGEN
Market Cap
$6.55B$11.14B
Volume
767,6581,259,263
Sector
TechnologyHealth
52-Week High
$341.08$194.57
52-Week Low
$90.03$102.87
Typical Hold Time
138 Days0 Days
Enterprise Value
$5.33B$11.02B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo (DUOL) trades at $139.73, down 5.42% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental performance with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a robust 39.9% profit margin. Recent earnings beats and analyst consensus of $142.50 price target suggest underlying strength despite recent price weakness. Technical indicators show a bullish moving average signal with neutral oscillators, while institutional sentiment remains mixed with notable insider selling activity.

Duolingo presents a compelling growth story with exceptional profitability metrics and consistent earnings outperformance. The primary investment opportunity lies in the company's AI-driven platform expansion and strong user growth momentum. Key risks include CEO share liquidations, competitive pressures in edtech, and valuation concerns at current levels. The stock's current discount to consensus target offers potential upside if execution continues.

Repligen Corporation Common Stock

RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.

Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DUOL
98% Buy2% Sell
Avg holding period · 138 Days
RGEN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL →

About Repligen Corporation Common Stock

Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.

Read more on RGEN →